English
简体中文
Total: £ 56.28
Published Date: 2024-09-13 | Pages: 97 | Tables: 210 | Pharma & Healthcare
A recombinant peptide therapy is produced through recombinant DNA technology. This involves inserting the DNA encoding the peptide into bacterial or mammalian cells, expressing the peptide in these cells and then purifying it from them.
The global market for Recombinant Peptide was estimated to be worth US$ 412 million in 2023 and is forecast to a readjusted size of US$ 701.4 million by 2030 with a CAGR of 6.6% during the forecast period 2024-2030
According to the "Global Use of Medicines 2023" released by IQVIA Institute, global pharmaceutical expenditures in 2022 will be approximately US$1.48 trillion (excluding costs related to COVID vaccines and therapies), and are forecast to grow at a rate of 3%-6% in the next few years. In terms of regional development trends, high-income countries such as Western Europe, North America and Japan are expected to grow at a slower rate in the next few years due to already high per capita usage, while growth markets such as Asia, Latin America and Eastern Europe will grow strongly. In terms of drug spending, China's drug spending in 2022 will be approximately US$166 billion. It is expected that drug expenditures will only increase in the next few years: from the perspective of demand, the trend of population aging, the increase in residents' wealth and the improvement of health awareness will drive the demand for drugs; from the perspective of national strategy, in 2016 , the State Council issued the "Healthy China 2030" Planning Outline, and "Healthy China" has been elevated to a national strategy; from the perspective of industry policies, it has experienced the uncertainty caused by the early stage of pharmaceutical reform, the implementation of centralized procurement policies and the revision of the drug reimbursement catalog The update will gradually achieve a dynamic balance with multiple goals such as promoting innovation, stabilizing supply, and reducing the burden on the public.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Recombinant Peptide, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Recombinant Peptide by region & country, by Type, and by Application.
The Recombinant Peptide market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Recombinant Peptide.
Market Segmentation
By Company
Sandoz Pharma
Stada Arzneimittel
Amgen
Hospira
Actavis
Cipla Ltd.
Wockhardt Ltd.
Biocon Ltd.
Segment by Type:
Glucagon
Calcitonin
Other
Segment by Application
Oncology
Blood Disorders
Infectious Diseases
Autoimmune Diseases
Other
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Recombinant Peptide manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Recombinant Peptide in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Recombinant Peptide in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Market Overview
1.1 Recombinant Peptide Product Introduction
1.2 Global Recombinant Peptide Market Size Forecast
1.2.1 Global Recombinant Peptide Sales Value (2019-2030)
1.2.2 Global Recombinant Peptide Sales Volume (2019-2030)
1.2.3 Global Recombinant Peptide Sales Price (2019-2030)
1.3 Recombinant Peptide Market Trends & Drivers
1.3.1 Recombinant Peptide Industry Trends
1.3.2 Recombinant Peptide Market Drivers & Opportunity
1.3.3 Recombinant Peptide Market Challenges
1.3.4 Recombinant Peptide Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Recombinant Peptide Players Revenue Ranking (2023)
2.2 Global Recombinant Peptide Revenue by Company (2019-2024)
2.3 Global Recombinant Peptide Players Sales Volume Ranking (2023)
2.4 Global Recombinant Peptide Sales Volume by Company Players (2019-2024)
2.5 Global Recombinant Peptide Average Price by Company (2019-2024)
2.6 Key Manufacturers Recombinant Peptide Manufacturing Base Distribution and Headquarters
2.7 Key Manufacturers Recombinant Peptide Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Recombinant Peptide
2.9 Recombinant Peptide Market Competitive Analysis
2.9.1 Recombinant Peptide Market Concentration Rate (2019-2024)
2.9.2 Global 5 and 10 Largest Manufacturers by Recombinant Peptide Revenue in 2023
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Recombinant Peptide as of 2023)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Glucagon
3.1.2 Calcitonin
3.1.3 Other
3.2 Global Recombinant Peptide Sales Value by Type
3.2.1 Global Recombinant Peptide Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Recombinant Peptide Sales Value, by Type (2019-2030)
3.2.3 Global Recombinant Peptide Sales Value, by Type (%) (2019-2030)
3.3 Global Recombinant Peptide Sales Volume by Type
3.3.1 Global Recombinant Peptide Sales Volume by Type (2019 VS 2023 VS 2030)
3.3.2 Global Recombinant Peptide Sales Volume, by Type (2019-2030)
3.3.3 Global Recombinant Peptide Sales Volume, by Type (%) (2019-2030)
3.4 Global Recombinant Peptide Average Price by Type (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Oncology
4.1.2 Blood Disorders
4.1.3 Infectious Diseases
4.1.4 Autoimmune Diseases
4.1.5 Other
4.2 Global Recombinant Peptide Sales Value by Application
4.2.1 Global Recombinant Peptide Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Recombinant Peptide Sales Value, by Application (2019-2030)
4.2.3 Global Recombinant Peptide Sales Value, by Application (%) (2019-2030)
4.3 Global Recombinant Peptide Sales Volume by Application
4.3.1 Global Recombinant Peptide Sales Volume by Application (2019 VS 2023 VS 2030)
4.3.2 Global Recombinant Peptide Sales Volume, by Application (2019-2030)
4.3.3 Global Recombinant Peptide Sales Volume, by Application (%) (2019-2030)
4.4 Global Recombinant Peptide Average Price by Application (2019-2030)
5 Segmentation by Region
5.1 Global Recombinant Peptide Sales Value by Region
5.1.1 Global Recombinant Peptide Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Recombinant Peptide Sales Value by Region (2019-2024)
5.1.3 Global Recombinant Peptide Sales Value by Region (2025-2030)
5.1.4 Global Recombinant Peptide Sales Value by Region (%), (2019-2030)
5.2 Global Recombinant Peptide Sales Volume by Region
5.2.1 Global Recombinant Peptide Sales Volume by Region: 2019 VS 2023 VS 2030
5.2.2 Global Recombinant Peptide Sales Volume by Region (2019-2024)
5.2.3 Global Recombinant Peptide Sales Volume by Region (2025-2030)
5.2.4 Global Recombinant Peptide Sales Volume by Region (%), (2019-2030)
5.3 Global Recombinant Peptide Average Price by Region (2019-2030)
5.4 North America
5.4.1 North America Recombinant Peptide Sales Value, 2019-2030
5.4.2 North America Recombinant Peptide Sales Value by Country (%), 2023 VS 2030
5.5 Europe
5.5.1 Europe Recombinant Peptide Sales Value, 2019-2030
5.5.2 Europe Recombinant Peptide Sales Value by Country (%), 2023 VS 2030
5.6 Asia Pacific
5.6.1 Asia Pacific Recombinant Peptide Sales Value, 2019-2030
5.6.2 Asia Pacific Recombinant Peptide Sales Value by Country (%), 2023 VS 2030
5.7 South America
5.7.1 South America Recombinant Peptide Sales Value, 2019-2030
5.7.2 South America Recombinant Peptide Sales Value by Country (%), 2023 VS 2030
5.8 Middle East & Africa
5.8.1 Middle East & Africa Recombinant Peptide Sales Value, 2019-2030
5.8.2 Middle East & Africa Recombinant Peptide Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Recombinant Peptide Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Recombinant Peptide Sales Value
6.2.1 Key Countries/Regions Recombinant Peptide Sales Value, 2019-2030
6.2.2 Key Countries/Regions Recombinant Peptide Sales Volume, 2019-2030
6.3 United States
6.3.1 United States Recombinant Peptide Sales Value, 2019-2030
6.3.2 United States Recombinant Peptide Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Recombinant Peptide Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Recombinant Peptide Sales Value, 2019-2030
6.4.2 Europe Recombinant Peptide Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Recombinant Peptide Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Recombinant Peptide Sales Value, 2019-2030
6.5.2 China Recombinant Peptide Sales Value by Type (%), 2023 VS 2030
6.5.3 China Recombinant Peptide Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Recombinant Peptide Sales Value, 2019-2030
6.6.2 Japan Recombinant Peptide Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Recombinant Peptide Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Recombinant Peptide Sales Value, 2019-2030
6.7.2 South Korea Recombinant Peptide Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Recombinant Peptide Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Recombinant Peptide Sales Value, 2019-2030
6.8.2 Southeast Asia Recombinant Peptide Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Recombinant Peptide Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Recombinant Peptide Sales Value, 2019-2030
6.9.2 India Recombinant Peptide Sales Value by Type (%), 2023 VS 2030
6.9.3 India Recombinant Peptide Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Sandoz Pharma
7.1.1 Sandoz Pharma Company Information
7.1.2 Sandoz Pharma Introduction and Business Overview
7.1.3 Sandoz Pharma Recombinant Peptide Sales, Revenue and Gross Margin (2019-2024)
7.1.4 Sandoz Pharma Recombinant Peptide Product Offerings
7.1.5 Sandoz Pharma Recent Development
7.2 Stada Arzneimittel
7.2.1 Stada Arzneimittel Company Information
7.2.2 Stada Arzneimittel Introduction and Business Overview
7.2.3 Stada Arzneimittel Recombinant Peptide Sales, Revenue and Gross Margin (2019-2024)
7.2.4 Stada Arzneimittel Recombinant Peptide Product Offerings
7.2.5 Stada Arzneimittel Recent Development
7.3 Amgen
7.3.1 Amgen Company Information
7.3.2 Amgen Introduction and Business Overview
7.3.3 Amgen Recombinant Peptide Sales, Revenue and Gross Margin (2019-2024)
7.3.4 Amgen Recombinant Peptide Product Offerings
7.3.5 Amgen Recent Development
7.4 Hospira
7.4.1 Hospira Company Information
7.4.2 Hospira Introduction and Business Overview
7.4.3 Hospira Recombinant Peptide Sales, Revenue and Gross Margin (2019-2024)
7.4.4 Hospira Recombinant Peptide Product Offerings
7.4.5 Hospira Recent Development
7.5 Actavis
7.5.1 Actavis Company Information
7.5.2 Actavis Introduction and Business Overview
7.5.3 Actavis Recombinant Peptide Sales, Revenue and Gross Margin (2019-2024)
7.5.4 Actavis Recombinant Peptide Product Offerings
7.5.5 Actavis Recent Development
7.6 Cipla Ltd.
7.6.1 Cipla Ltd. Company Information
7.6.2 Cipla Ltd. Introduction and Business Overview
7.6.3 Cipla Ltd. Recombinant Peptide Sales, Revenue and Gross Margin (2019-2024)
7.6.4 Cipla Ltd. Recombinant Peptide Product Offerings
7.6.5 Cipla Ltd. Recent Development
7.7 Wockhardt Ltd.
7.7.1 Wockhardt Ltd. Company Information
7.7.2 Wockhardt Ltd. Introduction and Business Overview
7.7.3 Wockhardt Ltd. Recombinant Peptide Sales, Revenue and Gross Margin (2019-2024)
7.7.4 Wockhardt Ltd. Recombinant Peptide Product Offerings
7.7.5 Wockhardt Ltd. Recent Development
7.8 Biocon Ltd.
7.8.1 Biocon Ltd. Company Information
7.8.2 Biocon Ltd. Introduction and Business Overview
7.8.3 Biocon Ltd. Recombinant Peptide Sales, Revenue and Gross Margin (2019-2024)
7.8.4 Biocon Ltd. Recombinant Peptide Product Offerings
7.8.5 Biocon Ltd. Recent Development
8 Industry Chain Analysis
8.1 Recombinant Peptide Industrial Chain
8.2 Recombinant Peptide Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Recombinant Peptide Sales Model
8.5.2 Sales Channel
8.5.3 Recombinant Peptide Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
List of Tables
Table 1. Recombinant Peptide Market Trends
Table 2. Recombinant Peptide Market Drivers & Opportunity
Table 3. Recombinant Peptide Market Challenges
Table 4. Recombinant Peptide Market Restraints
Table 5. Global Recombinant Peptide Revenue by Company (2019-2024) & (US$ Million)
Table 6. Global Recombinant Peptide Revenue Market Share by Company (2019-2024)
Table 7. Global Recombinant Peptide Sales Volume by Company (2019-2024) & (K Units)
Table 8. Global Recombinant Peptide Sales Volume Market Share by Company (2019-2024)
Table 9. Global Market Recombinant Peptide Price by Company (2019-2024) & (US$/Unit)
Table 10. Key Manufacturers Recombinant Peptide Manufacturing Base Distribution and Headquarters
Table 11. Key Manufacturers Recombinant Peptide Product Type
Table 12. Key Manufacturers Time to Begin Mass Production of Recombinant Peptide
Table 13. Global Recombinant Peptide Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Recombinant Peptide as of 2023)
Table 15. Mergers & Acquisitions, Expansion Plans
Table 16. Global Recombinant Peptide Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
Table 17. Global Recombinant Peptide Sales Value by Type (2019-2024) & (US$ Million)
Table 18. Global Recombinant Peptide Sales Value by Type (2025-2030) & (US$ Million)
Table 19. Global Recombinant Peptide Sales Market Share in Value by Type (2019-2024) & (%)
Table 20. Global Recombinant Peptide Sales Market Share in Value by Type (2025-2030) & (%)
Table 21. Global Recombinant Peptide Sales Volume by Type: 2019 VS 2023 VS 2030 (K Units)
Table 22. Global Recombinant Peptide Sales Volume by Type (2019-2024) & (K Units)
Table 23. Global Recombinant Peptide Sales Volume by Type (2025-2030) & (K Units)
Table 24. Global Recombinant Peptide Sales Market Share in Volume by Type (2019-2024) & (%)
Table 25. Global Recombinant Peptide Sales Market Share in Volume by Type (2025-2030) & (%)
Table 26. Global Recombinant Peptide Price by Type (2019-2024) & (US$/Unit)
Table 27. Global Recombinant Peptide Price by Type (2025-2030) & (US$/Unit)
Table 28. Global Recombinant Peptide Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
Table 29. Global Recombinant Peptide Sales Value by Application (2019-2024) & (US$ Million)
Table 30. Global Recombinant Peptide Sales Value by Application (2025-2030) & (US$ Million)
Table 31. Global Recombinant Peptide Sales Market Share in Value by Application (2019-2024) & (%)
Table 32. Global Recombinant Peptide Sales Market Share in Value by Application (2025-2030) & (%)
Table 33. Global Recombinant Peptide Sales Volume by Application: 2019 VS 2023 VS 2030 (K Units)
Table 34. Global Recombinant Peptide Sales Volume by Application (2019-2024) & (K Units)
Table 35. Global Recombinant Peptide Sales Volume by Application (2025-2030) & (K Units)
Table 36. Global Recombinant Peptide Sales Market Share in Volume by Application (2019-2024) & (%)
Table 37. Global Recombinant Peptide Sales Market Share in Volume by Application (2025-2030) & (%)
Table 38. Global Recombinant Peptide Price by Application (2019-2024) & (US$/Unit)
Table 39. Global Recombinant Peptide Price by Application (2025-2030) & (US$/Unit)
Table 40. Global Recombinant Peptide Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Global Recombinant Peptide Sales Value by Region (2019-2024) & (US$ Million)
Table 42. Global Recombinant Peptide Sales Value by Region (2025-2030) & (US$ Million)
Table 43. Global Recombinant Peptide Sales Value by Region (2019-2024) & (%)
Table 44. Global Recombinant Peptide Sales Value by Region (2025-2030) & (%)
Table 45. Global Recombinant Peptide Sales Volume by Region (K Units): 2019 VS 2023 VS 2030
Table 46. Global Recombinant Peptide Sales Volume by Region (2019-2024) & (K Units)
Table 47. Global Recombinant Peptide Sales Volume by Region (2025-2030) & (K Units)
Table 48. Global Recombinant Peptide Sales Volume by Region (2019-2024) & (%)
Table 49. Global Recombinant Peptide Sales Volume by Region (2025-2030) & (%)
Table 50. Global Recombinant Peptide Average Price by Region (2019-2024) & (US$/Unit)
Table 51. Global Recombinant Peptide Average Price by Region (2025-2030) & (US$/Unit)
Table 52. Key Countries/Regions Recombinant Peptide Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
Table 53. Key Countries/Regions Recombinant Peptide Sales Value, (2019-2024) & (US$ Million)
Table 54. Key Countries/Regions Recombinant Peptide Sales Value, (2025-2030) & (US$ Million)
Table 55. Key Countries/Regions Recombinant Peptide Sales Volume, (2019-2024) & (K Units)
Table 56. Key Countries/Regions Recombinant Peptide Sales Volume, (2025-2030) & (K Units)
Table 57. Sandoz Pharma Company Information
Table 58. Sandoz Pharma Introduction and Business Overview
Table 59. Sandoz Pharma Recombinant Peptide Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 60. Sandoz Pharma Recombinant Peptide Product Offerings
Table 61. Sandoz Pharma Recent Development
Table 62. Stada Arzneimittel Company Information
Table 63. Stada Arzneimittel Introduction and Business Overview
Table 64. Stada Arzneimittel Recombinant Peptide Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 65. Stada Arzneimittel Recombinant Peptide Product Offerings
Table 66. Stada Arzneimittel Recent Development
Table 67. Amgen Company Information
Table 68. Amgen Introduction and Business Overview
Table 69. Amgen Recombinant Peptide Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 70. Amgen Recombinant Peptide Product Offerings
Table 71. Amgen Recent Development
Table 72. Hospira Company Information
Table 73. Hospira Introduction and Business Overview
Table 74. Hospira Recombinant Peptide Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 75. Hospira Recombinant Peptide Product Offerings
Table 76. Hospira Recent Development
Table 77. Actavis Company Information
Table 78. Actavis Introduction and Business Overview
Table 79. Actavis Recombinant Peptide Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 80. Actavis Recombinant Peptide Product Offerings
Table 81. Actavis Recent Development
Table 82. Cipla Ltd. Company Information
Table 83. Cipla Ltd. Introduction and Business Overview
Table 84. Cipla Ltd. Recombinant Peptide Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 85. Cipla Ltd. Recombinant Peptide Product Offerings
Table 86. Cipla Ltd. Recent Development
Table 87. Wockhardt Ltd. Company Information
Table 88. Wockhardt Ltd. Introduction and Business Overview
Table 89. Wockhardt Ltd. Recombinant Peptide Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 90. Wockhardt Ltd. Recombinant Peptide Product Offerings
Table 91. Wockhardt Ltd. Recent Development
Table 92. Biocon Ltd. Company Information
Table 93. Biocon Ltd. Introduction and Business Overview
Table 94. Biocon Ltd. Recombinant Peptide Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 95. Biocon Ltd. Recombinant Peptide Product Offerings
Table 96. Biocon Ltd. Recent Development
Table 97. Key Raw Materials Lists
Table 98. Raw Materials Key Suppliers Lists
Table 99. Recombinant Peptide Downstream Customers
Table 100. Recombinant Peptide Distributors List
Table 101. Research Programs/Design for This Report
Table 102. Key Data Information from Secondary Sources
Table 103. Key Data Information from Primary Sources
List of Figures
Figure 1. Recombinant Peptide Product Picture
Figure 2. Global Recombinant Peptide Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
Figure 3. Global Recombinant Peptide Sales Value (2019-2030) & (US$ Million)
Figure 4. Global Recombinant Peptide Sales Volume (2019-2030) & (K Units)
Figure 5. Global Recombinant Peptide Sales Price (2019-2030) & (US$/Unit)
Figure 6. Recombinant Peptide Report Years Considered
Figure 7. Global Recombinant Peptide Players Revenue Ranking (2023) & (US$ Million)
Figure 8. Global Recombinant Peptide Players Sales Volume Ranking (2023) & (K Units)
Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Recombinant Peptide Revenue in 2023
Figure 10. Recombinant Peptide Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 11. Glucagon Picture
Figure 12. Calcitonin Picture
Figure 13. Other Picture
Figure 14. Global Recombinant Peptide Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 15. Global Recombinant Peptide Sales Value Market Share by Type, 2023 & 2030
Figure 16. Global Recombinant Peptide Sales Volume by Type (2019 VS 2023 VS 2030) & (K Units)
Figure 17. Global Recombinant Peptide Sales Volume Market Share by Type, 2023 & 2030
Figure 18. Global Recombinant Peptide Price by Type (2019-2030) & (US$/Unit)
Figure 19. Product Picture of Oncology
Figure 20. Product Picture of Blood Disorders
Figure 21. Product Picture of Infectious Diseases
Figure 22. Product Picture of Autoimmune Diseases
Figure 23. Product Picture of Other
Figure 24. Global Recombinant Peptide Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 25. Global Recombinant Peptide Sales Value Market Share by Application, 2023 & 2030
Figure 26. Global Recombinant Peptide Sales Volume by Application (2019 VS 2023 VS 2030) & (K Units)
Figure 27. Global Recombinant Peptide Sales Volume Market Share by Application, 2023 & 2030
Figure 28. Global Recombinant Peptide Price by Application (2019-2030) & (US$/Unit)
Figure 29. North America Recombinant Peptide Sales Value (2019-2030) & (US$ Million)
Figure 30. North America Recombinant Peptide Sales Value by Country (%), 2023 VS 2030
Figure 31. Europe Recombinant Peptide Sales Value (2019-2030) & (US$ Million)
Figure 32. Europe Recombinant Peptide Sales Value by Country (%), 2023 VS 2030
Figure 33. Asia Pacific Recombinant Peptide Sales Value (2019-2030) & (US$ Million)
Figure 34. Asia Pacific Recombinant Peptide Sales Value by Country (%), 2023 VS 2030
Figure 35. South America Recombinant Peptide Sales Value (2019-2030) & (US$ Million)
Figure 36. South America Recombinant Peptide Sales Value by Country (%), 2023 VS 2030
Figure 37. Middle East & Africa Recombinant Peptide Sales Value (2019-2030) & (US$ Million)
Figure 38. Middle East & Africa Recombinant Peptide Sales Value by Country (%), 2023 VS 2030
Figure 39. Key Countries/Regions Recombinant Peptide Sales Value (%), (2019-2030)
Figure 40. Key Countries/Regions Recombinant Peptide Sales Volume (%), (2019-2030)
Figure 41. United States Recombinant Peptide Sales Value, (2019-2030) & (US$ Million)
Figure 42. United States Recombinant Peptide Sales Value by Type (%), 2023 VS 2030
Figure 43. United States Recombinant Peptide Sales Value by Application (%), 2023 VS 2030
Figure 44. Europe Recombinant Peptide Sales Value, (2019-2030) & (US$ Million)
Figure 45. Europe Recombinant Peptide Sales Value by Type (%), 2023 VS 2030
Figure 46. Europe Recombinant Peptide Sales Value by Application (%), 2023 VS 2030
Figure 47. China Recombinant Peptide Sales Value, (2019-2030) & (US$ Million)
Figure 48. China Recombinant Peptide Sales Value by Type (%), 2023 VS 2030
Figure 49. China Recombinant Peptide Sales Value by Application (%), 2023 VS 2030
Figure 50. Japan Recombinant Peptide Sales Value, (2019-2030) & (US$ Million)
Figure 51. Japan Recombinant Peptide Sales Value by Type (%), 2023 VS 2030
Figure 52. Japan Recombinant Peptide Sales Value by Application (%), 2023 VS 2030
Figure 53. South Korea Recombinant Peptide Sales Value, (2019-2030) & (US$ Million)
Figure 54. South Korea Recombinant Peptide Sales Value by Type (%), 2023 VS 2030
Figure 55. South Korea Recombinant Peptide Sales Value by Application (%), 2023 VS 2030
Figure 56. Southeast Asia Recombinant Peptide Sales Value, (2019-2030) & (US$ Million)
Figure 57. Southeast Asia Recombinant Peptide Sales Value by Type (%), 2023 VS 2030
Figure 58. Southeast Asia Recombinant Peptide Sales Value by Application (%), 2023 VS 2030
Figure 59. India Recombinant Peptide Sales Value, (2019-2030) & (US$ Million)
Figure 60. India Recombinant Peptide Sales Value by Type (%), 2023 VS 2030
Figure 61. India Recombinant Peptide Sales Value by Application (%), 2023 VS 2030
Figure 62. Recombinant Peptide Industrial Chain
Figure 63. Recombinant Peptide Manufacturing Cost Structure
Figure 64. Channels of Distribution (Direct Sales, and Distribution)
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed
